 Kathleen Gavin
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenopause | 6 | 2020 | 123 | 1.690 |
Why?
| | Estrogens | 6 | 2020 | 364 | 1.650 |
Why?
| | Adipocytes | 7 | 2025 | 223 | 1.410 |
Why?
| | Leptin | 3 | 2025 | 247 | 1.400 |
Why?
| | Adipose Tissue | 5 | 2022 | 643 | 1.140 |
Why?
| | Lipolysis | 2 | 2020 | 44 | 1.000 |
Why?
| | Energy Metabolism | 5 | 2022 | 927 | 0.960 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 321 | 0.850 |
Why?
| | Adipogenesis | 3 | 2023 | 56 | 0.780 |
Why?
| | Hyperthyroidism | 1 | 2023 | 21 | 0.780 |
Why?
| | Hypothyroidism | 1 | 2023 | 67 | 0.750 |
Why?
| | Subcutaneous Fat | 2 | 2013 | 79 | 0.740 |
Why?
| | Estradiol | 5 | 2021 | 507 | 0.730 |
Why?
| | Ovary | 3 | 2020 | 226 | 0.720 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2018 | 212 | 0.720 |
Why?
| | Adiponectin | 2 | 2022 | 240 | 0.710 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 42 | 0.560 |
Why?
| | Exercise | 6 | 2018 | 2183 | 0.550 |
Why?
| | Hematopoietic Stem Cells | 4 | 2025 | 419 | 0.550 |
Why?
| | Adipose Tissue, Brown | 1 | 2018 | 60 | 0.550 |
Why?
| | Postmenopause | 5 | 2012 | 390 | 0.530 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2018 | 72 | 0.530 |
Why?
| | Integrin beta1 | 1 | 2017 | 33 | 0.510 |
Why?
| | Pituitary-Adrenal System | 1 | 2018 | 163 | 0.490 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2018 | 196 | 0.480 |
Why?
| | Testosterone | 1 | 2020 | 412 | 0.470 |
Why?
| | Body Composition | 7 | 2022 | 689 | 0.470 |
Why?
| | Adipocytes, White | 1 | 2015 | 19 | 0.460 |
Why?
| | Stem Cells | 2 | 2017 | 621 | 0.430 |
Why?
| | Sex Characteristics | 1 | 2020 | 776 | 0.420 |
Why?
| | Telemedicine | 1 | 2023 | 957 | 0.400 |
Why?
| | Buttocks | 1 | 2013 | 14 | 0.390 |
Why?
| | Ovarian Neoplasms | 3 | 2026 | 589 | 0.380 |
Why?
| | Abdominal Fat | 1 | 2013 | 50 | 0.370 |
Why?
| | Ovariectomy | 3 | 2026 | 163 | 0.370 |
Why?
| | Estrogen Receptor alpha | 2 | 2013 | 151 | 0.350 |
Why?
| | Hysterectomy | 1 | 2012 | 137 | 0.340 |
Why?
| | Menopause | 3 | 2022 | 319 | 0.340 |
Why?
| | Overweight | 2 | 2013 | 606 | 0.340 |
Why?
| | Insulin | 1 | 2022 | 2502 | 0.330 |
Why?
| | Receptors, Estrogen | 1 | 2013 | 400 | 0.310 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2009 | 203 | 0.280 |
Why?
| | Cell Differentiation | 4 | 2023 | 2037 | 0.270 |
Why?
| | Female | 25 | 2026 | 78301 | 0.260 |
Why?
| | Vascular Stiffness | 1 | 2012 | 485 | 0.260 |
Why?
| | Salpingo-oophorectomy | 1 | 2026 | 19 | 0.240 |
Why?
| | Adult | 17 | 2026 | 40486 | 0.230 |
Why?
| | Cell Lineage | 2 | 2017 | 376 | 0.210 |
Why?
| | Mice | 6 | 2025 | 18261 | 0.210 |
Why?
| | Rosaniline Dyes | 1 | 2023 | 15 | 0.200 |
Why?
| | Humans | 27 | 2026 | 144665 | 0.200 |
Why?
| | Middle Aged | 12 | 2026 | 35968 | 0.190 |
Why?
| | Genetic Counseling | 2 | 2023 | 81 | 0.190 |
Why?
| | Carotid Arteries | 3 | 2012 | 207 | 0.190 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 949 | 0.180 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 65 | 0.180 |
Why?
| | Animals | 7 | 2025 | 37948 | 0.170 |
Why?
| | Obesity | 2 | 2023 | 3070 | 0.170 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 206 | 0.160 |
Why?
| | Genetic Testing | 2 | 2023 | 480 | 0.160 |
Why?
| | Histone Deacetylases | 1 | 2022 | 207 | 0.160 |
Why?
| | Lysine | 1 | 2022 | 271 | 0.150 |
Why?
| | Cardiovascular Diseases | 3 | 2022 | 2172 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2018 | 2033 | 0.140 |
Why?
| | Aged, 80 and over | 3 | 2023 | 8283 | 0.140 |
Why?
| | Cortisone | 1 | 2018 | 16 | 0.140 |
Why?
| | Telephone | 1 | 2019 | 176 | 0.140 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 147 | 0.130 |
Why?
| | Gonadal Steroid Hormones | 2 | 2021 | 143 | 0.130 |
Why?
| | Mothers | 1 | 2023 | 765 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2021 | 886 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2025 | 1241 | 0.120 |
Why?
| | Fibrin | 1 | 2017 | 84 | 0.120 |
Why?
| | Resistance Training | 2 | 2018 | 185 | 0.120 |
Why?
| | Cell Fusion | 1 | 2015 | 48 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2017 | 146 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2018 | 297 | 0.120 |
Why?
| | Dexamethasone | 1 | 2018 | 366 | 0.120 |
Why?
| | Leuprolide | 1 | 2015 | 21 | 0.110 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2015 | 52 | 0.110 |
Why?
| | Young Adult | 4 | 2023 | 14119 | 0.110 |
Why?
| | Bone Density | 2 | 2015 | 484 | 0.110 |
Why?
| | Internet | 1 | 2019 | 698 | 0.100 |
Why?
| | Phentolamine | 1 | 2013 | 19 | 0.100 |
Why?
| | Adiposity | 1 | 2018 | 529 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Estrogen Receptor beta | 1 | 2013 | 40 | 0.090 |
Why?
| | Isoproterenol | 1 | 2013 | 96 | 0.090 |
Why?
| | Adrenergic beta-Agonists | 1 | 2013 | 92 | 0.090 |
Why?
| | Adolescent | 3 | 2023 | 22405 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 677 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1246 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 231 | 0.080 |
Why?
| | Aged | 3 | 2023 | 25955 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1098 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1161 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2023 | 17147 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2184 | 0.080 |
Why?
| | Ascorbic Acid | 3 | 2006 | 171 | 0.080 |
Why?
| | Oxidative Stress | 2 | 2006 | 1338 | 0.080 |
Why?
| | Biopsy | 1 | 2013 | 1079 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2017 | 4110 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2012 | 717 | 0.070 |
Why?
| | Macrophages | 1 | 2017 | 1496 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2009 | 364 | 0.070 |
Why?
| | Ultrasonography | 1 | 2012 | 776 | 0.070 |
Why?
| | Menstrual Cycle | 1 | 2009 | 140 | 0.070 |
Why?
| | Lipids | 1 | 2013 | 706 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5869 | 0.060 |
Why?
| | Vasodilation | 1 | 2009 | 520 | 0.060 |
Why?
| | Vasoconstriction | 1 | 2006 | 216 | 0.060 |
Why?
| | Femoral Artery | 1 | 2006 | 190 | 0.060 |
Why?
| | Antioxidants | 2 | 2006 | 546 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2009 | 894 | 0.050 |
Why?
| | DNA Methylation | 1 | 2009 | 664 | 0.050 |
Why?
| | Polyuria | 1 | 2023 | 2 | 0.050 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 241 | 0.050 |
Why?
| | Hypertrophy | 1 | 2023 | 128 | 0.050 |
Why?
| | Male | 3 | 2022 | 72425 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5967 | 0.050 |
Why?
| | 3T3-L1 Cells | 1 | 2022 | 36 | 0.040 |
Why?
| | Acylation | 1 | 2022 | 30 | 0.040 |
Why?
| | Treatment Failure | 1 | 2023 | 365 | 0.040 |
Why?
| | Perimenopause | 1 | 2022 | 66 | 0.040 |
Why?
| | Polysaccharides | 1 | 2021 | 86 | 0.040 |
Why?
| | Glycosylation | 1 | 2021 | 161 | 0.040 |
Why?
| | Prospective Studies | 2 | 2026 | 7994 | 0.040 |
Why?
| | Counseling | 1 | 2023 | 405 | 0.040 |
Why?
| | United States | 2 | 2019 | 16018 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 353 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 88 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2022 | 3603 | 0.030 |
Why?
| | Risk Factors | 1 | 2012 | 10796 | 0.030 |
Why?
| | Compliance | 2 | 2006 | 49 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2821 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1726 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2022 | 3109 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2591 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1044 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1928 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2019 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2350 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5185 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2005 | 37 | 0.010 |
Why?
| | Elasticity | 1 | 2005 | 188 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2006 | 513 | 0.010 |
Why?
| | Norepinephrine | 1 | 2005 | 196 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 359 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2015 | 11734 | 0.010 |
Why?
|
|
Gavin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|